March 25, 2021
Med BioGene Inc. Reports Audited Financial Results for 2020.
November 06, 2020
Med BioGene Inc. Reports Financial Results for Q3, 2020.
April 29, 2020
Med BioGene Inc. Reports Audited Financial Results for 2019.
November 29, 2019
Med BioGene Inc. Reports Financial Results for Q3 2019.
April 16, 2019
Med BioGene Inc. Reports Audited Financial Results for 2018.
November 09, 2018
Med BioGene Inc. Reports Financial Results for Q3, 2018.
August 28, 2018
Med BioGene Inc. Reports Financial Results for Q2, 2018.
April 30, 2018
Med BioGene Inc. Reports Audited Financial Results for 2017.
November 22, 2017
Med BioGene Inc. Reports Financial Results for Q3 2017.
April 28, 2017
Med Biogene Reports Audited Financial Results for 2016
November 17, 2016
Med BioGene Inc. Reports Financial Results for Q3 2016
Aug 28, 2016
Med BioGene Inc. Reports Financial Results for Q2 2016
May 30, 2016
Med Biogene Reports Financial Results for Q1 2016
April 21, 2016
Med Biogene Reports Audited Financial Results for 2015
November 26, 2015
Med Biogene Reports Financial Results for Q3 2015
Dec 15, 2015
Med BioGene licensee to begin GeneFX logistics in Q1
September 10, 2015
Med BioGene - Background on GeneFx® Lung Commercialization
August 21, 2015
Med Biogene Reports Financial Results for Q2 2015
June 21, 2015
From activist to CEO, how Iain Weir Jones landed the top job at Med Bio-Gene
June 1, 2015
MedBiogene Provides Update
May 29, 2015
Med Biogene Reports Financial Results for Q1 2015
May 21, 2015
Med BioGene Issues Revised Fact Sheet
May 21, 2015
Med BioGene Engages IR Company
April 29, 2015
Med Biogene Reports Financial Results for 2014
April 9, 2015
Additional International Exposure for MBI’s commercialization Partner
March 26, 2015
Neil Campbell, the CEO of Helomics®, Message on Cancer Video
March 26, 2015
First 10 Industry Partners Announced
March 26, 2015
Helomics - 100,000 Genomes Project
March 3, 2015
Appointment Of New Director
February 16, 2015
MBI Closes Shares For Debt Transaction
February 3, 2015
Med BioGene Provide Shareholders Update
January 13, 2015
MBI Announces Shares For Debt Transaction
November 30, 2014
Med Biogene Reports Financial Result for Q3 2014
October 02, 2014
Status Update Precision Therapeutics Inc. to Med Biogene Inc.
October 01, 2014
Closing of Private Placement
September 05, 2014
Directors Nominated By Dissident Shareholder Elected At Annual General Meeting
September 04, 2014
Med BioGene Announces Receipt of Proxies for Upcoming Annual and Special Meeting
August 29, 2014
Med BioGene Reports Financial Results for Q2 2014
August 21, 2014
Med BioGene Responds to Assertions Made by Dissident Shareholder
August 15, 2014
Med BioGene Provides Update and Announces Proposed Financing
August 06, 2014
Med BioGene Announces Director Nominations and Postponement of Annual and Special Meeting
March 24, 2014
Med BioGene Announces Regulatory Approval of GeneFx® Lung
Welcome to Med BioGene
Med BioGene Inc. (MBI: TSX Venture) is a life science company focused on the development and commercialization of genomic-based clinical laboratory diagnostic tests.
Med BioGene’s lead test under development is GeneFx® Lung (formerly, LungExpress Dx), a proprietary gene expression-based test to improve upon staging for identifying those patients with early-stage non-small-cell lung cancer (NSCLC) who, following surgical removal of their tumor, are at higher and lower risks of mortality. In an initial study of patient specimens from the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial, published in the Journal of Clinical Oncology, patients classified by GeneFx Lung as higher risk benefited from adjuvant chemotherapy, and those classified as lower risk did not benefit and may have experienced a detrimental effect from adjuvant chemotherapy. GeneFx Lung was subsequently validated in predicting patient mortality in four independent studies involving data from tumor specimens totaling 676 untreated early-stage NSCLC patients. GeneFx Lung is expected to provide better-informed and personalized treatment decisions to assist in the selection of patients for adjuvant chemotherapy.
On April 15, 2011, Precision Therapeutics, Inc. and Med BioGene closed their commercialization agreement. The agreement provides to Precision exclusive global rights to develop and commercialize GeneFx Lung.
For more information on Precision Therapeutics, please see www.precisiontherapeutics.com.
© Copyright 2006 - Med BioGene Inc. - Legal Disclaimer